Stoke Therapeutics (STOK) Total Liabilities (2018 - 2026)
Stoke Therapeutics (STOK) posted quarterly Total Liabilities of $48.4 million for Q1 2026, down 14.81% year-over-year from $56.8 million in Q1 2025, and down 26.64% quarter-over-quarter from $66.0 million in Q4 2025.
Stoke Therapeutics (STOK) Total Liabilities (2018 - 2026) Analysis & Trends
Stoke Therapeutics' Total Liabilities history runs 9 years deep, the most recent figure standing at $48.4 million for Q1 2026.
- In Q1 2026, Total Liabilities fell 14.81% year-over-year to $48.4 million; the TTM figure through Mar 2026 stood at $48.4 million (down 14.81% YoY), while the FY2025 annual figure was $66.0 million, up 55.12% from the prior year.
- Total Liabilities for Q1 2026 stood at $48.4 million, down from $66.0 million in the prior quarter.
- The five-year high for Total Liabilities was $77.1 million in Q2 2022, with the low at $42.5 million in Q4 2024.
- The 5-year median for Total Liabilities is $66.0 million (2025), against an average of $63.2 million.
- The sharpest annual moves came in 2022 and 2024: Total Liabilities surged 351.98% in 2022, then sank 38.16% in 2024.
- Stoke Therapeutics' Total Liabilities stood at $71.2 million in 2022, then dropped by 3.43% to $68.8 million in 2023, then slumped by 38.16% to $42.5 million in 2024, then soared by 55.12% to $66.0 million in 2025, then decreased by 26.64% to $48.4 million in 2026.
- Business Quant data shows STOK's Total Liabilities at $48.4 million in Q1 2026, $66.0 million in Q4 2025, and $52.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | 48.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 48.42 Mn |
| Mar 31, 2026 | 48.40 Mn |
| Dec 31, 2025 | 65.98 Mn |
| Sep 30, 2025 | 52.16 Mn |
| Jun 30, 2025 | 49.57 Mn |
| Mar 31, 2025 | 56.81 Mn |
| Dec 31, 2024 | 42.53 Mn |
| Sep 30, 2024 | 61.21 Mn |
| Jun 30, 2024 | 65.05 Mn |
| Mar 31, 2024 | 64.84 Mn |
| Dec 31, 2023 | 68.78 Mn |
| Sep 30, 2023 | 66.89 Mn |
| Jun 30, 2023 | 66.72 Mn |
| Mar 31, 2023 | 67.97 Mn |
| Dec 31, 2022 | 71.22 Mn |
| Sep 30, 2022 | 73.48 Mn |
| Jun 30, 2022 | 77.11 Mn |
| Mar 31, 2022 | 75.96 Mn |
| Dec 31, 2021 | 21.09 Mn |
| Sep 30, 2021 | 16.26 Mn |